bpc-157 stable oral form Peptide Therapy BPC-157 & The Gut-Brain Axis:

The main ongoing studies: REDEFINE 1 , Phase 3 obesity without T2D (results 20242025, preliminarily 25.3 %) REDEFINE 2 , Phase 3 obesity + T2D REDEFINE 3 , Phase 3 cardiovascular outcome trial (n~7000) Stand-alone clinical development of Cagrilintide is limited , Novo Nordisk is primarily investing in the CagriSema combination

Most common side effects were gastrointestinal, with 24.5% of participants in the phase 2 obesity trial discontinuing efinopegdutide 10 mg due to AE however when the same dose was used with gradual escalation at the MASLD trial (starting dose 2.4 mg for 4 weeks, then 5 mg for 4 weeks and then 10 mg), only 5.6% of participants discontinued the medication due to AE

Management of endocrine disease: Are all GLP-1 agonists equal in the treatment of type 2 diabetes

Why its notable: animal and preclinical studies support BPC-157s role in mucosal and soft-tissue healing, and its become a go-to for patients with digestive issues or slow-healing soft-tissue injuries